Sermorelin

A GHRH analog used to stimulate the body's own growth hormone production.

Written by Anthivera EditorialPending medical review

Updated Regulatory status verified May 1, 2026

Compounded

Relevance for women

A GHRH analog with the longest clinical history of any GH-axis peptide. Currently compoundable in the U.S. (a separate regulatory status from the Category 2 group). Relevant to women for body composition, sleep, and recovery in midlife.

Where the evidence sits

Anthivera’s calibrated five-tier scale — what the strongest evidence on Sermorelin actually supports today.

  1. Preclinical
  2. Limited clinicalSermorelin
  3. Multiple human studies
  4. Phase 3
  5. FDA-approved

Limited clinical: Small open-label or case-report data in humans.

Questions to bring to a consult

  1. 01What evidence is there for Sermorelin in women specifically — and does that include perimenopausal or postmenopausal cohorts?
  2. 02What is the current FDA regulatory status, and which compounding pharmacy will my prescription go through?
  3. 03What baseline labs do you require before starting, and how often do you monitor?
  4. 04What are the realistic timelines and what does “not working for you” look like in practice?

Articles on Sermorelin

Providers that offer Sermorelin

See the full provider comparison for all peptides side by side.

Related peptides in hormone & gh-axis